Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute. Learn more about Cancer Currents.
-
Patient with Brain Tumor Responds Dramatically to Targeted TherapyA patient with a papillary craniopharyngioma saw his tumor shrink more than 80 percent after treatment with a targeted drug that inhibits a mutant form of the BRAF protein.
-
Lung Cancer Precision Medicine Trials: Adapting to ProgressPatients with lung cancer are benefiting from the boom in targeted and immune-based therapies. With a series of precision medicine trials, NCI is keeping pace with the rapidly changing treatment landscape for lung cancer.
-
FDA Approves Talimogene Laherparepvec to Treat Metastatic MelanomaThe FDA has approved the first oncolytic virus therapy, talimogene laherparepvec (T-VEC). The drug was approved for the treatment of metastatic melanoma that cannot be removed surgically.
-
FDA Approves Irinotecan Liposome to Treat Pancreatic CancerPatients with metastatic pancreatic cancer that has progressed after receiving gemcitabine-based chemotherapy now have a new treatment option: irinotecan liposome in combination with fluorouracil and leucovorin.
-
How Genomics Is Shaping Precision Medicine in OncologyIn laboratories at NCI and around the world, researchers are using advanced genomic technologies to study the differences between cancer cells and normal cells, leading to new and more effective treatments for patients with cancer.
-
FDA Approves Pembrolizumab for Patients with Non-Small Cell Lung CancerThe FDA has approved the drug pembrolizumab to treat patients with advanced non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1.
-
Bringing Precision to Screening for CancerA recent NCI-sponsored conference brought together leading screening and cancer control researchers to discuss the state of the science of precision screening for five cancers.
-
Low Income Is a Barrier to Clinical Trial Enrollment, Study SuggestsA new study has found that patients with annual household incomes below $50,000 were less likely to participate in a cancer clinical trial than those with higher incomes.
-
Antioxidants Accelerate the Growth and Invasiveness of Tumors in MiceMetastatic tumor cells are particularly sensitive to oxidative stress, and antioxidant supplementation increases their ability to grow and metastasize.
-
FDA Approves Nivolumab for Some Melanomas and Lung CancersThe FDA has approved nivolumab in combination with ipilimumab for advanced melanoma and nivolumab alone for advanced nonsquamous lung cancer.
-
A Holistic Approach to Cancer Health DisparitiesRecognizing that complex factors underlie health disparities, NCI is taking a holistic approach in our efforts to address this serious public health issue.
-
Patients with Advanced Cancer May Benefit from Discussing Prognosis with PhysiciansPatients with advanced cancer may benefit from having discussions about their prognoses with their physicians.
-
Study Identifies New Opportunities for Targeted ImmunotherapyA team of NCI researchers has reported that several types of gastrointestinal cancer have tumor-specific mutations that can be recognized by the immune system, thereby offering a new therapeutic opportunity for patients with these tumors.
-
In Triple-Negative Breast Cancer, Targeting an AddictionA new approach to disrupting genes that promote the development and spread of tumors may hold promise for treating an aggressive and difficult-to-treat type of breast cancer.
-
Bringing Cancer Research to the Public: NCI’s Networks and ProgramsA number of NCI programs and networks are the foundation of the National Cancer Program and play a critical role in promoting progress.
-
Long-Term Study Finds No Increased Risk of Miscarriage after HPV VaccinationWomen in a clinical trial who became pregnant after vaccination with a bivalent human papillomavirus (HPV) vaccine did not have an increased risk of miscarriage.
-
New on NCI’s WebsitesNCI periodically provides updates on new websites and other online content of interest to the cancer community.
-
FDA Approves Combination Drug for Patients with Advanced Colorectal CancerThe FDA has approved a single drug that combines trifluridine and tipiracil to treat patients with metastatic colorectal cancer whose disease progressed after standard treatment.
-
Progress against Cancer: The Role of Basic ScienceActing NCI Director Doug Lowy, M.D., discusses the critical contribution of basic science in fostering progress against cancer.
-
TCGA Wins 2015 Sammies People’s Choice AwardThe Partnership for Public Service presented the 2015 People’s Choice Award to the government staff and researchers who have worked on The Cancer Genome Atlas.